These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

611 related articles for article (PubMed ID: 25583164)

  • 1. Sofosbuvir and Ribavirin for Treatment of Chronic Hepatitis C in Patients Coinfected With Hepatitis C Virus and HIV: The Impact on Patient-Reported Outcomes.
    Younossi ZM; Stepanova M; Sulkowski M; Naggie S; Puoti M; Orkin C; Hunt SL
    J Infect Dis; 2015 Aug; 212(3):367-77. PubMed ID: 25583164
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sofosbuvir and ribavirin for hepatitis C in patients with HIV coinfection.
    Sulkowski MS; Naggie S; Lalezari J; Fessel WJ; Mounzer K; Shuhart M; Luetkemeyer AF; Asmuth D; Gaggar A; Ni L; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Rodriguez-Torres M; Dieterich D;
    JAMA; 2014 Jul 23-30; 312(4):353-61. PubMed ID: 25038354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study.
    Molina JM; Orkin C; Iser DM; Zamora FX; Nelson M; Stephan C; Massetto B; Gaggar A; Ni L; Svarovskaia E; Brainard D; Subramanian GM; McHutchison JG; Puoti M; Rockstroh JK;
    Lancet; 2015 Mar; 385(9973):1098-106. PubMed ID: 25659285
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon-Free Treatment of Hepatitis C Virus in HIV/Hepatitis C Virus-Coinfected Subjects Results in Increased Serum Low-Density Lipoprotein Concentration.
    Townsend K; Meissner EG; Sidharthan S; Sampson M; Remaley AT; Tang L; Kohli A; Osinusi A; Masur H; Kottilil S
    AIDS Res Hum Retroviruses; 2016 May; 32(5):456-62. PubMed ID: 26559180
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sofosbuvir and Velpatasvir Combination Improves Patient-reported Outcomes for Patients With HCV Infection, Without or With Compensated or Decompensated Cirrhosis.
    Younossi ZM; Stepanova M; Feld J; Zeuzem S; Sulkowski M; Foster GR; Mangia A; Charlton M; O'Leary JG; Curry MP; Nader F; Henry L; Hunt S
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):421-430.e6. PubMed ID: 27847279
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patient-reported outcomes in chronic hepatitis C patients with cirrhosis treated with sofosbuvir-containing regimens.
    Younossi ZM; Stepanova M; Nader F; Jacobson IM; Gane E; Nelson D; Lawitz E; Hunt SL
    Hepatology; 2014 Jun; 59(6):2161-9. PubMed ID: 24710669
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
    Jacobson IM; Gordon SC; Kowdley KV; Yoshida EM; Rodriguez-Torres M; Sulkowski MS; Shiffman ML; Lawitz E; Everson G; Bennett M; Schiff E; Al-Assi MT; Subramanian GM; An D; Lin M; McNally J; Brainard D; Symonds WT; McHutchison JG; Patel K; Feld J; Pianko S; Nelson DR; ;
    N Engl J Med; 2013 May; 368(20):1867-77. PubMed ID: 23607593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison.
    Swallow E; Song J; Yuan Y; Kalsekar A; Kelley C; Peeples M; Mu F; Ackerman P; Signorovitch J
    Clin Ther; 2016 Feb; 38(2):404-12. PubMed ID: 26839044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir for chronic hepatitis C virus infection genotype 1-4 in patients coinfected with HIV.
    Rodriguez-Torres M; Gaggar A; Shen G; Kirby B; Svarovskaia E; Brainard D; Symonds WT; McHutchison JG; Gonzalez M; Rodriguez-Orengo J
    J Acquir Immune Defic Syndr; 2015 Apr; 68(5):543-9. PubMed ID: 25622055
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir and ribavirin in HCV genotypes 2 and 3.
    Zeuzem S; Dusheiko GM; Salupere R; Mangia A; Flisiak R; Hyland RH; Illeperuma A; Svarovskaia E; Brainard DM; Symonds WT; Subramanian GM; McHutchison JG; Weiland O; Reesink HW; Ferenci P; Hézode C; Esteban R;
    N Engl J Med; 2014 May; 370(21):1993-2001. PubMed ID: 24795201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease.
    Charlton M; Everson GT; Flamm SL; Kumar P; Landis C; Brown RS; Fried MW; Terrault NA; O'Leary JG; Vargas HE; Kuo A; Schiff E; Sulkowski MS; Gilroy R; Watt KD; Brown K; Kwo P; Pungpapong S; Korenblat KM; Muir AJ; Teperman L; Fontana RJ; Denning J; Arterburn S; Dvory-Sobol H; Brandt-Sarif T; Pang PS; McHutchison JG; Reddy KR; Afdhal N;
    Gastroenterology; 2015 Sep; 149(3):649-59. PubMed ID: 25985734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported outcomes assessment in chronic hepatitis C treated with sofosbuvir and ribavirin: the VALENCE study.
    Younossi ZM; Stepanova M; Zeuzem S; Dusheiko G; Esteban R; Hezode C; Reesink HW; Weiland O; Nader F; Hunt SL
    J Hepatol; 2014 Aug; 61(2):228-34. PubMed ID: 24713186
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The combination of simeprevir and sofosbuvir is more effective than that of peginterferon, ribavirin, and sofosbuvir for patients with hepatitis C-related Child's class A cirrhosis.
    Pearlman BL; Ehleben C; Perrys M
    Gastroenterology; 2015 Apr; 148(4):762-70.e2; quiz e11-2. PubMed ID: 25557952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Mangia A; Wyles D; Rodriguez-Torres M; Hassanein T; Gordon SC; Schultz M; Davis MN; Kayali Z; Reddy KR; Jacobson IM; Kowdley KV; Nyberg L; Subramanian GM; Hyland RH; Arterburn S; Jiang D; McNally J; Brainard D; Symonds WT; McHutchison JG; Sheikh AM; Younossi Z; Gane EJ
    N Engl J Med; 2013 May; 368(20):1878-87. PubMed ID: 23607594
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sofosbuvir and ribavirin for treatment of compensated recurrent hepatitis C virus infection after liver transplantation.
    Charlton M; Gane E; Manns MP; Brown RS; Curry MP; Kwo PY; Fontana RJ; Gilroy R; Teperman L; Muir AJ; McHutchison JG; Symonds WT; Brainard D; Kirby B; Dvory-Sobol H; Denning J; Arterburn S; Samuel D; Forns X; Terrault NA
    Gastroenterology; 2015 Jan; 148(1):108-17. PubMed ID: 25304641
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Daclatasvir plus sofosbuvir, with or without ribavirin, in real-world patients with HIV-HCV coinfection and advanced liver disease.
    Rockstroh JK; Ingiliz P; Petersen J; Peck-Radosavljevic M; Welzel TM; Van der Valk M; Zhao Y; Jimenez-Exposito MJ; Zeuzem S
    Antivir Ther; 2017; 22(3):225-236. PubMed ID: 27845298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.